Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $57.32 USD
Change Today +0.07 / 0.12%
Volume 732.5K
As of 8:04 PM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

resmed inc (RMD) Key Developments

ResMed Inc. Provides Update on Phase III SERVE-HF Study of Adaptive Servo-Ventilation (Asv) Therapy

ResMed Inc. announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was designed to assess whether the treatment of moderate to severe predominant central sleep apnea with Adaptive Servo-Ventilation (ASV) therapy could reduce mortality and morbidity in patients with symptomatic chronic heart failure in addition to optimized medical care. The study did not show a statistically significant difference between patients randomized to ASV therapy and those in the control group in the primary endpoint of time to all-cause mortality or unplanned hospitalization for worsening heart failure (based on a hazard ratio [HR] = 1.136, 95% confidence interval [95% CI] = (0.974, 1.325), p-value = 0.104). A preliminary analysis of the data identified a statistically significant 2.5% absolute increased risk of cardiovascular mortality for those patients in the trial who received ASV therapy per year compared to those in the control group. In the study, the cardiovascular mortality rate in the ASV group was 10% per year compared to 7.5% per year in the control group. There were no issues associated with the performance of the ASV therapy device in the trial.

ResMed Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2015; Provides Gross Margin Outlook for Fourth Quarter of 2015; Provides Tax Rate Outlook for the Full Year 2015

ResMed Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2015. For the quarter, the company’s net revenue was $422,497,000 against $397,758,000 a year ago. Income from operations was $105,868,000 against $104,698,000 a year ago. Income before income tax was $114,358,000 against $112,912,000 a year ago. Net income was $90,983,000 against $89,969,000 a year ago. Diluted earnings per share were $0.64 against $0.63 a year ago. Non-GAAP operating income (excluding the impact of amortization of acquired intangible assets) was $108,071,000 against $107,157,000 a year ago. Non-GAAP net income (excluding the impact of amortization of acquired intangible assets) was $92,626,000 against $91,837,000 a year ago. Non-GAAP diluted earnings per share (excluding the impact of amortization of acquired intangible assets) were $0.65 against $0.64 a year ago. Cash flow from operations was $90.9 million for the quarter, reflecting strong underlying earnings and a modestly increasing working capital. Capital expenditure for the quarter was $10.6 million while depreciation and amortization for the March quarter totaled $17.9 million. For the nine months, the company’s net revenue was $1,225,848,000 against $1,139,762,000 a year ago. Income from operations was $309,689,000 against $306,601,000 a year ago. Income before income tax was $331,800,000 against $324,443,000 a year ago. Net income was $265,424,000 against $257,535,000 a year ago. Diluted earnings per share were $1.86 against $1.78 a year ago. Net cash provided by operating activities was $283,479,000 against $275,685,000 a year ago. Purchases of property, plant and equipment was $50,266,000 against $54,210,000 a year ago. Non-GAAP operating income (excluding the impact of amortization of acquired intangible assets) was $316,247,000 against $313,926,000 a year ago. Non-GAAP net income (excluding the impact of amortization of acquired intangible assets) was $270,375,000 against $263,098,000 a year ago. Non-GAAP diluted earnings per share (excluding the impact of amortization of acquired intangible assets) were $1.90 against $1.82 a year ago. Patent registration costs were $7,109,000 against $5,691,000 a year ago. For the fourth quarter of 2015, the company expects gross margin to be broadly consistent with third quarter being in the range of 59% to 60%, assuming current exchange rates. Gross margin drivers like currency fluctuations and geographic and product mix could swing this range further if they move beyond their expectations. The company estimates its effective tax rate for the full fiscal year 2015 will be in the range of 20% to 21%.

ResMed Inc. Declares Quarterly Dividend, Payable on June 18, 2015

The ResMed board of directors declared a quarterly dividend of $0.28 per share. The dividend will have a record date of May 21, 2015, payable on June 18, 2015. The ex-dividend date will be May 19, 2015 for common stock holders and for CDI holders.

ResMed Inc. to Report Q3, 2015 Results on Apr 23, 2015

ResMed Inc. announced that they will report Q3, 2015 results at 1:30 PM, Pacific Standard Time on Apr 23, 2015

ResMed Inc., Q3 2015 Earnings Call, Apr 23, 2015

ResMed Inc., Q3 2015 Earnings Call, Apr 23, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RMD:US $57.32 USD +0.07

RMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
IDEXX Laboratories Inc $138.03 USD +0.89
Mettler-Toledo International Inc $330.84 USD -0.46
PerkinElmer Inc $53.39 USD -0.19
Teleflex Inc $128.91 USD +1.24
Cooper Cos Inc/The $179.80 USD -2.98
View Industry Companies
 

Industry Analysis

RMD

Industry Average

Valuation RMD Industry Range
Price/Earnings 23.1x
Price/Sales 4.9x
Price/Book 5.2x
Price/Cash Flow 22.3x
TEV/Sales 4.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESMED INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.